Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Melanoma 4Carcinoma, Renal Cell 4Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1

Interventions

zanubrutinib 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × B-cell Malignancies × tislelizumab × Clear all
NCT04170283 2025-10-21

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

BeOne Medicines

Phase 3 Active not recruiting
955 enrolled
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡